This study investigates hepatocellular carcinoma (HCC), which is a type of liver cancer. The purpose is to understand how the investigational medication affects patients with HCC, both with and without portal vein tumor thrombosis (PVTT). HCC is diagnosed using imaging tests or a combination of imaging and blood tests, or a liver biopsy.
Participants will undergo various procedures to monitor their health and the effects of the investigational medication. These procedures may include imaging tests and blood tests to assess the progression of HCC and the body's response to the treatment.
- Who can participate: Adults over 18 years old with confirmed hepatocellular carcinoma (HCC) are eligible. Participants must not have had prior locoregional therapy or liver transplantation and should not be on certain medications like vitamin K or antibiotics.
- Study details: Participants will receive an investigational medication to assess its effects on HCC. A placebo may be used for comparison.
How understandable was the trial content above?
Hard to understand
Easy to understand
